Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.

Abstract: A method is performed at an electronic device including one or more processors and a non-transitory memory. The method includes obtaining a first spherical Gaussian (SG) lobe that characterizes ambient light from a physical environment. The method may include determining the first SG lobe based on a 360 degree image of the physical environment. The first SG lobe indicates a first directional characteristic associated with the ambient light. The method includes determining a first plurality of sampling rays based on the first directional characteristic. The method includes obtaining a depth value that is associated with a computer-generated object. The depth value may be from a depth buffer, which is populated with the depth value during rendering of the computer-generated object. The method includes generating a shadow that is associated with the computer-generated object, based on the depth value and a first sampling ray of the first plurality of sampling rays.

Abstract: Techniques for capturing spoken user inputs while a device is prevented from capturing such spoken user inputs are described. When a first device becomes incapable of capturing spoken user inputs intended for a system, a second device, for capturing such spoken user inputs, may be identified. The second device may be identified based on the second device being connected to a same vehicle computing system as the first device. The second device may be enabled to capture spoken user inputs, intended for the system, until the first device is again able to capture such spoken user inputs.

Abstract: The present disclosure relates to solid state forms of Sugammadex sodium, processes for preparation thereof and pharmaceutical compositions thereof.

Abstract: The invention refers to an isolated antibody that specifically binds to O25b antigen of E. coli strains comprising at least an antibody heavy chain variable region (VH), which comprises any of the CDR1 to CDR3 sequences as listed in FIG. 1, and optionally further comprising an antibody light chain variable region (VL), which comprises any of the CDR4 to CDR6 sequences as listed in FIG. 1, or functionally active CDR variants of any of the forgoing CDR 1-6 sequences.

Abstract: Generating an expressive avatar includes obtaining an expressive image of a face, and determining at least one target levels of detail for a representation of the face. A trained convolutional neural network model is applied to the expressive image of the face to obtain a mesh representation of the face at each of the at least one target levels of detail, wherein each convolution in the trained convolutional neural network model provides a unique level of detail, and an avatar is generated based on the mesh representation of the face at least of the at least one target levels of detail.

Abstract: A Shigella vaccine preparation comprising 10E8-10E12 CFU of a live, genetically attenuated Shigella flexneri strain that comprises a chromosomal deletion of setBA and which is non-invasive as determined by the Sereny test and an in vitro invasion assay using HeLa cells, wherein the strain comprises an endogenous invasion plasmid that is genetically engineered to incorporate a heterologous expression construct expressing a pathogen-specific antigen.

Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.

Abstract: A calixarene compound in an antiviral effective amount for use as an antiviral substance in a pharmaceutical preparation for use in prophylactic or therapeutic treatment of a disease condition which is caused by or associated with an infection with a virus.

Abstract: A fault monitoring device may monitor and detect for faults corresponding to a high-side voltage rail, to low-side voltage rail, or internally within a voltage source connected to the high-side voltage rail and the low-side voltage rail. The fault monitoring device may determine sample voltage levels and/or sample resistance values to detect the faults. Also, in various embodiments, the fault monitoring device may perform one or more fault monitoring processes over multiple stages. The fault monitoring device may determine the sample voltage levels and/or the sample resistance values while switching a secondary resistance circuit in different states over the multiple stages.

Abstract: A fault monitoring device may monitor and detect for faults corresponding to a high-side voltage rail, to low-side voltage rail, or internally within a voltage source connected to the high-side voltage rail and the low-side voltage rail. The fault monitoring device may determine sample voltage levels and/or sample resistance values to detect the faults. Also, in various embodiments, the fault monitoring device may perform one or more fault monitoring processes over multiple stages. The fault monitoring device may determine the sample voltage levels and/or the sample resistance values while switching a secondary resistance circuit in different states over the multiple stages.

Abstract: The invention provides for an isolated antibody that specifically recognizes a galactan-III epitope of the lipopolysaccharide (LPS) O-antigen structure of Klebsiella pneumoniae, which epitope is incorporated in galactan-III repeating units, wherein the galactan-III repeating unit is a branched galactose homopolymer of Formula (I). The invention further provides for a pharmaceutical or diagnostic preparation comprising said antibody, and a method of producing said antibody.

Abstract: An Azelastine compound in an antiviral effective amount for use as an antiviral substance in a pharmaceutical preparation for use in prophylactic or therapeutic treatment of a subject in need of antiviral treatment.

Abstract: A fault monitoring device may monitor and detect for faults corresponding to a high-side voltage rail, to low-side voltage rail, or internally within a voltage source connected to the high-side voltage rail and the low-side voltage rail. The fault monitoring device may determine sample voltage levels and/or sample resistance values to detect the faults. Also, in various embodiments, the fault monitoring device may perform one or more fault monitoring processes over multiple stages. The fault monitoring device may determine the sample voltage levels and/or the sample resistance values while switching a secondary resistance circuit in different states over the multiple stages.

Abstract: A fault monitoring device may monitor and detect for faults corresponding to a high-side voltage rail, to low-side voltage rail, or internally within a voltage source connected to the high-side voltage rail and the low-side voltage rail. The fault monitoring device may determine sample voltage levels and/or sample resistance values to detect the faults. Also, in various embodiments, the fault monitoring device may perform one or more fault monitoring processes over multiple stages. The fault monitoring device may determine the sample voltage levels and/or the sample resistance values while switching a secondary resistance circuit in different states over the multiple stages.

Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.

Abstract: The invention provides for an isolated antibody that specifically recognizes a galactan-III epitope of the lipopolysaccharide (LPS) O-antigen structure of Klebsiella pneumoniae, which epitope is incorporated in galactan-III repeating units, wherein the galactan-III repeating unit is a branched galactose homopolymer of Formula (I). The invention further provides for a pharmaceutical or diagnostic preparation comprising said antibody, and a method of producing said antibody.

Abstract: A method of treating a subject in need of anti-coronavirus treatment by providing a prophylactic or therapeutic treatment which includes an antiviral effective amount of an Azelastine compound, where the antiviral effective amount is 0.1-500 ?g per dose. An Azelastine compound can also be used as an antiviral substance in a medicinal product for treating a biological surface to prevent coronavirus infection and/or coronavirus spread, or as a viral disinfectant.

Abstract: An electromechanical motor vehicle power steering system having a multiphase, permanently excited electric motor via a controller and supply lines from an onboard power supply of a motor vehicle.

Abstract: The present disclosure describes multi-well plates comprising a frame made of a first material having an array of a plurality of holes arranged in a columnar pattern on the top surface and an array of segmented breaking features arranged in a linear columnar pattern which alternates with the columnar pattern of the plurality of holes, and a plurality of tubes/wells made of a second material placed into the plurality of holes, wherein the multi-well plate is manually divisible along the segmented breaking features into one or more columns of multi-well/tube strips. Manually dividing multi-well plate of the disclosure produces multi-well strips or segments that have smooth edges, thereby reducing injuries and glove tear incidences.